souseikai global clinical research center

A letter from our CEO in response to COVID-19 outbreak

March 31, 2020

Dear Valued Customers and partners

Medical group SOUSEIKAI and I sincerely share our heartfelt empathies with everyone impacted by CoVID-19.

It is a time where we need to communicate and work together more than ever to protect our community and pass on a safe and healthy world to future generations.

I understand the industry we are currently in is tremendously important in times like these, and It is our honor that we could be a part of the process to deliver the vaccines and effective treatments to save lives as quickly as possible.

Fortunately, we have been able to operate studies in a calm and safe environment so far while mitigating risks to our employees and community. SOUSEIKAI keeps our guard up and keeps on striving to protect the health and safety of our site staff and their families, our customers, study participants, patients, and communities, as well as ensuring the clinical trials are going forward without much troubles or delays.

As a medical group that has hospitals throughout the nation, we are well aware and prepared with the measures to be taken at epidemic situations like this. We are maintaining social distancing in all possible tasks, checking the subjects’ and staff’s health more often and more thoroughly, and we will follow strict quarantine rules in alignment with the most up-to-date government guidance if needed. First of all, hand-washing is in our culture!

Also, we are committed to accommodating any specific needs and changes, including remote/risk-based monitoring and even direct data capturing.

Please don’t hesitate to let us know how we can serve you better and support your goal in these difficult times.

Finally, I wish you all good health and prosperity.

Thank you for your continued support.

Shin Irie MD
Executive Director
SOUSEIKAI Global Clinical Research Center, Japan